A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis (UC)
Crohn's Disease

Interventions

DRUG: Risankizumab
DRUG: Cytochrome P450 (CYP) Substrates

Sponsor

AbbVie